Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients

Table 1 Characteristics of individuals included in the study

Variable	Control	AD	DLB
Number of subjects (M/F)^a	36 (16/20)	45 (13/32)	29 (12/17)
Age (yr)^a	62 (44–82)	76 (61–86)***	74 (63–84)***
MMSE (score)^a	29 (26–30)^b	20 (7–29)^b,***	20 (7–27)***
P-tau (ng/L)^c	46.33 ± 18.37^d	105.25 ± 41.76^e,***	57.96 ± 20.47^f
T-tau (ng/L)^c	287.68 ± 133.62^g	823.10 ± 340.67^f,***	412.69 ± 169.36^f
Aβ_1–42 (ng/L)^c	713.45 ± 213.58^g	352.71 ± 101.59^f,***	457.31 ± 195.32^f,***
α-Synuclein (pg/ml)^c	693.61 ± 194.71	781.68 ± 222.25^b,***	585.01 ± 216.44^b,**
IL-6 (pg/ml)^c	1.17 ± 1.10	1.37 ± 1.09	0.90 ± 1.23**

Aβ _1–42 amyloid-β peptide 1–42, AD Alzheimer’s disease, DLB dementia with Lewy bodies, IL interleukin, MMSE Mini Mental State Examination, P-tau phosphorylated tau, T-tau total tau
^aData are presented as median (range)
^bData missing for one participant
^cData are presented as mean ± SD
^dData missing for 15 participants
^eData missing for 13 participants
^fData missing for three participants
^gData missing for 14 participants
***Indicates a significant difference at the p < 0.001 level compared with controls
**Indicates a significant difference at the p < 0.01 level compared with controls

ISSN: 1758-9193